Druggability & Clinical Context
Druggability
Low
Score: 0.39
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
7
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Druggability Rationale: SLC16A2 presents a challenging druggability profile (0.30 score) due to its transporter nature and inherent structural constraints in targeting substrate-binding pockets on membrane proteins. However, the existence of investigational thyroid hormone analogs (triiodothyroacetic acid) and multiple high-resolution crystal structures (best resolution 3.0 Å) demonstrate feasibility for substrate supplementation approaches, though allosteric modulation remains underdeveloped.
Mechanism: Substrate supplementation or transporter modulation
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:Triiodothyroacetic acid (investigational) — MCT8 deficiency
Structural Data:PDB (7) ✓AlphaFold ✓Cryo-EM ✓
Selectivity & Safety Considerations
Selectivity is a major challenge given MCT8's tissue-specific expression in brain and peripheral tissues; off-target transport of substrates to other SLC16 family members (MCT1, MCT4, MCT10) could cause systemic effects. Conversely, the restricted CNS penetration requirement and X-linked inheritance pattern offer a natural selectivity advantage for brain-targeted thyroid hormone analogs over systemic monocarboxylate transporters.